METTL3 and cancer: Indeed, STC-15, an orally bioavailable small molecule inhibitor of METTL3 in Phase 1 clinical study, can restrain the growth of AML cell lines and patient-derived AML samples with sub-micromolar to 1 micromolar IC50 values through activation of anti-cancer immune responses (84).